PolyPid (PYPD) CFO details extensive employee stock option awards

Rhea-AI Filing Summary

PolyPid Ltd. Chief Financial Officer Jonathan Missulawin filed an initial ownership report listing multiple employee stock options over Ordinary Shares. These options cover various blocks of shares, including 64,500 underlying shares at an exercise price of 4.6400 and 42,000 underlying shares at 2.6700, with expirations ranging from 2027 to 2035. The filing records existing derivative holdings and does not show any stock purchases or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Missulawin Jonathan

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock option (right to buy)	04/01/2017	03/08/2027	Ordinary Shares	20(1)	$123.01	D
Employee Stock option (right to buy)	02/02/2018	11/02/2027	Ordinary Shares	60(2)	$23.07	D
Employee Stock option (right to buy)	05/06/2020	02/06/2030	Ordinary Shares	16(3)	$23.07	D
Employee Stock option (right to buy)	06/11/2021	06/11/2030	Ordinary Shares	1,083(4)	$23.07	D
Employee Stock option (right to buy)	05/09/2023	05/09/2032	Ordinary Shares	1,167(5)	$23.07	D
Employee Stock option (right to buy)	08/09/2022	08/09/2031	Ordinary Shares	667(6)	$23.07	D
Employee Stock option (right to buy)	08/07/2024	08/07/2033	Ordinary Shares	10,000(7)	$11.01	D
Employee Stock option (right to buy)	08/06/2024	05/06/2034	Ordinary Shares	64,500(8)	$4.64	D
Employee Stock option (right to buy)	06/09/2025	05/06/2034	Ordinary Shares	43,000(9)	$4.64	D
Employee Stock option (right to buy)	08/12/2025	05/12/2035	Ordinary Shares	42,000(10)	$2.67	D
Employee Stock option (right to buy)	06/09/2025	05/12/2035	Ordinary Shares	28,000(11)	$2.67	D

Explanation of Responses:

1. The options were granted on March 8, 2017 and fully vested as of March 8, 2020.

2. The options were granted on November 2, 2017 and fully vested as of November 2, 2020.

3. The options were granted on February 6, 2020 and fully vested as of February 6, 2023.

4. The options were granted on June 11, 2020 and vest on a quarterly basis beginning September 11, 2021 until June 11, 2024.

5. The options were granted on May 9, 2022 and vest on a quarterly basis beginning August 9, 2023 until May 9, 2026.

6. The options were granted on August 9, 2021 and vest on a quarterly basis beginning November 9, 2022 until August 9, 2025.

7. The options were granted on August 7, 2023 and vest on a quarterly basis beginning November 7, 2024 until August 7, 2027.

8. The options were granted on May 6, 2024 and vest on a quarterly basis until May 6, 2028.

9. The options were granted on May 6, 2024 and vest on a quarterly basis until May 6, 2026.

10. The options were granted on May 12, 2025 and vest on a quarterly basis until May 12, 2029.

11. The options were granted on May 12, 2025 and vest on a quarterly basis until May 12, 2027.

	/s/ Jonathan Missulawin	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does PolyPid (PYPD) CFO Jonathan Missulawin report in this Form 3?

He reports his existing employee stock option holdings over PolyPid Ordinary Shares. The filing lists multiple option grants with specific exercise prices, vesting schedules, and expiration dates, but does not disclose any new stock purchases or sales.

How many PolyPid (PYPD) shares are covered by the CFO’s largest option grants?

The largest reported option grants cover 64,500 underlying Ordinary Shares at an exercise price of 4.6400, 43,000 shares at 4.6400, 42,000 shares at 2.6700, and 28,000 shares at 2.6700, along with several smaller historical grants.

What are the exercise price ranges of the PolyPid (PYPD) CFO’s stock options?

The options have exercise prices from 2.6700 up to 123.0100 per Ordinary Share. Lower-priced grants are more recent, while the highest-priced grant of 20 underlying shares at 123.0100 dates back to an earlier option program.

When do the PolyPid (PYPD) CFO’s stock options expire?

The reported options expire on dates between 2027-03-08 and 2035-05-12. Earlier grants, such as those granted in 2017, expire in 2027, while later grants, including those tied to 2025 awards, expire in 2035.

Does this PolyPid (PYPD) Form 3 show the CFO buying or selling shares?

No, it does not show any buying or selling of shares. The transactions are classified as holdings, and the transaction summary reports zero buys, zero sells, and 11 holding entries reflecting existing employee stock option positions.

What do the vesting footnotes in the PolyPid (PYPD) CFO Form 3 explain?

The footnotes describe grant dates and vesting schedules for each option award. Some option grants were already fully vested by dates like March 8, 2020, while others vest quarterly over multi‑year periods ending between 2026 and 2029.